Pharma Report on Pulmonary Arterial Hypertension – Pipeline Review, H2 2020


Pulmonary Arterial Hypertension – Pipeline Review, H2 2020


Pulmonary Arterial Hypertension – Pipeline Review, H2 2020, provides an overview of the Pulmonary Arterial Hypertension (Cardiovascular) pipeline landscape.

Pulmonary arterial hypertension (PAH) is a type of high blood pressure that occurs in the right side of the heart and in the arteries that supply blood to the lungs. Symptoms include chest pain, fatigue, passing out suddenly, and swelling of the legs (edema). Risk factors include family history, age, obesity, obstructive sleep apnea and other diseases, including congenital heart disease, lung disease, liver disease and connective tissue disorders like scleroderma and lupus. Treatment includes sildenafil, prostanoids and calcium channel blockers.

Report Highlights

Pulmonary Arterial Hypertension – Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Pulmonary Arterial Hypertension and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 1, 10, 15, 13, 1, 46, 16 and 3 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 8 molecules, respectively.

Pulmonary Arterial Hypertension (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


– The pipeline guide provides a snapshot of the global therapeutic landscape of Pulmonary Arterial Hypertension (Cardiovascular).
– The pipeline guide reviews pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Pulmonary Arterial Hypertension (Cardiovascular) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Pulmonary Arterial Hypertension (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Pulmonary Arterial Hypertension (Cardiovascular)

Reasons to Buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Pulmonary Arterial Hypertension (Cardiovascular).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Pulmonary Arterial Hypertension (Cardiovascular) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned:
Aadi Bioscience Inc
Abivax SA
Acceleron Pharma Inc
Aerami Therapeutics
Aerogen Ltd
Aerovate Therapeutics Inc
AI Therapeutics Inc
Altavant Sciences Inc
Alterras Therapeutics GmbH
APEIRON Biologics AG
Apollo Therapeutics LLC
APT Therapeutics Inc
Aqualung Therapeutics Corp
ATXA Therapeutics Ltd
AVEO Pharmaceuticals Inc
Bayer AG
Bial – Portela & Ca SA
Biogen Inc
Biozeus Pharmaceutical SA
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
C4X Discovery Holdings Plc
Camurus AB
Capricor Therapeutics Inc
Celsion Corp
Celtaxsys Inc
Cereno Scientific AB
Chiesi Farmaceutici SpA
Complexa Inc
Denovo Biopharma LLC
Eli Lilly and Co
Excubio Pharmaceuticals Inc
Galectin Therapeutics Inc
GenThera Inc
GEXVal Inc
Gilead Sciences Inc
Gmax Biopharm Ltd
Gossamer Bio Inc
Hanmi Pharmaceuticals Co Ltd
Insmed Inc
Insys Therapeutics Inc
Interprotein Corp
INVENT Pharmaceuticals Inc
Johnson & Johnson
Keros Therapeutics Inc
Liquidia Technologies Inc
LTT Bio-Pharma Co Ltd
Martin Pharmaceuticals Inc
Merck & Co Inc
Mezzion Pharma Co Ltd
Morphogen-IX Ltd
Nadian Bio Ltd
Nippon Shinyaku Co Ltd
Nissan Chemical Corp
Northern Therapeutics Inc
Novartis AG
Pfizer Inc
Pharmosa Biopharm Inc
PhaseBio Pharmaceuticals Inc
PHPrecisionMed LLC
Proteo Inc
Pulmokine Inc
Q BioMed Inc
Radikal Therapeutics Inc
Recursion Pharmaceuticals Inc
Relief Therapeutics Holding AG
Respira Therapeutics Inc
Resverlogix Corp
Reviva Pharmaceuticals Inc
Ribomic Inc
Shijiazhuang Zhikang Hongren New Drug Development Co Ltd
Sosei Heptares
SteadyMed Therapeutics Inc
Suda Pharmaceuticals Ltd
Sulfateq BV
Topadur Pharma AG
Translate Bio Inc
Tritech Biopharmaceuticals Co Ltd
United Therapeutics Corp
Vascular BioSciences
Vasculonics LLC
VasThera Co Ltd
Velocity Pharmaceutical Development LLC
Vivus Inc

For queries regarding this report:

Contact Us:
Ritesh Tiwari, Director
USA: +1-800-416-3124

Follow us on Social Media:

Ritesh Tiwari is the Founder of Research By Markets. He has more than 7 years experience in the Market Research industry and a total experience spanning 18+ years. His core experience is in Sales and International Recruitments. Ritesh is a big foodie and a huge football fan, supporting Manchester United (EPL) and FC Barcelona (La Liga). He hardly misses watching any matches when these teams are playing. Get in touch with Ritesh via: *Industry Press Release is a part of Research By Markets.